Evaluation of White Sweet Potato Tube Feeding Formula on Type 2 Diabetic Residents in Long-term Care Institutions

Taipei Medical University

Status

Completed

Conditions

Type 2 Diabetes

Treatments

Dietary Supplement: Commercial diabetic formula

Dietary Supplement: White sweet potato formula

Study type

Interventional

Funder types

Other

Identifiers

NCT02711839

201505027

Details and patient eligibility

About

In order to response the increasing of aging population cause losing ability that need long-care needs, the project entitled "10-year long-term care program" from Executive Yuan in 2007 is carried out to assist economically disadvantaged and disabled elderly to acquire daily nutrition. Therefore, the long-term care resident's nutritional status got more attention than before. Out of control in blood glucose will not only increase bed sores and urinary tract infection in tube feeding residents but also rise medical expenditures. The nutritional status of long-term care institutions, anyang homes and nursing home are generally bad in nutrition management due to high cost of nutritional supplements from foreign imports that cause the burden of families. In this study, we will recruit diabetic subjects that divide into white sweet potato group (experimental group) and commercial formula group (control group) by using randomized, parallel and open clinical study through tube feeding in sixty days.

Full description

All subjects will be evaluated the blood sugar and clinical nutrition assessment such as postural measurement, urine test and blood biomarker examination.

Enrollment

54 patients

Sex

All

Ages

30 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Long-term stability nasogastric or gastrostomy-fed person.
The physician diagnosed as diabetic and regular use of hypoglycemic drugs.

Exclusion criteria

Psychosis or depression.
Hba1c> 8.5%.
High taking nutritional supplements or steroids drugs.
Have undergone abdominal surgery caused by intestinal sticky.
Suffering from cancer, ulcers, respiratory infections and other diseases.
Currently receiving central venous nutrition therapy or intravenous nutrition therapy.
Liver dysfunction (ALT ≧ 100 U / L), renal insufficiency (creatinine ≧ 3mg / dl), heart failure (NYFc II above), moderate anemia (hemoglobin <9 g / dl).